'EverX' Participates in CES to Promote 'Mora' in Musculoskeletal Digital Healthcare

Musculoskeletal disease digital healthcare company EverX announced on the 15th that it participated in CES, the world's largest electronics and IT exhibition held in Las Vegas, USA, from the 9th to the 12th (local time), promoting its rehabilitation and exercise therapy solution ‘MORA’.

At the EverX booth set up at CES 2024, CEO Yoon Chan (back right) is explaining 'Mora' to visitors.
[Photo by EverX]

EverX's participation in CES marks the second consecutive year following last year. Notably, this year MORA received the CES Innovation Award, and the company also introduced a new solution called 'MORA Care' for musculoskeletal self-management for office workers, which is planned to be launched domestically later this month.

MORA Care is a corporate employee health welfare service platform designed to expand MORA’s scope into B2B services. It was developed based on MORA’s core assets: a medically evidence-based rehabilitation exercise curriculum and AI-based posture estimation technology. It aims to prevent musculoskeletal diseases that are common chronic ailments among office workers, such as forward head posture and back pain, which tend to occur or worsen in work environments, and to enhance adherence through personalized exercise programs. MORA Care provides musculoskeletal rehabilitation and exercise services that were previously difficult to access due to spatial and temporal constraints, enabling management and prevention of musculoskeletal diseases that are important throughout the life cycle, thereby expected to reduce disease incidence and socio-economic costs.

Yoon Chan, CEO of EverX, said, "MORA is proving its value in musculoskeletal disease rehabilitation and exercise therapy, an area with globally unmet needs, through personalized rehabilitation and advanced AI technology." He added, "We will diversify our platform to provide digital musculoskeletal disease rehabilitation exercise solutions that benefit not only medical professionals, hospitals, and patients but also corporations and individuals."

EverX is also developing 'MORA Cure,' Korea’s first digital therapeutic device (DTx) for musculoskeletal diseases targeting patellofemoral pain syndrome and chronic low back pain. The plan is to complete exploratory clinical trials for both indications within this year and proceed to confirmatory clinical trials.

This content was produced with the assistance of AI translation services.